KIAA1429 Monoklonaler Antikörper

KIAA1429 Monoklonal Antikörper für WB, IHC, FC (Intra), Indirect ELISA

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human, Maus

Anwendung

WB, IHC, FC (Intra), Indirect ELISA

Konjugation

Unkonjugiert

CloneNo.

3F1A4

Kat-Nr. : 68235-1-PBS

Synonyme

VIRMA, 3F1A4, MSTP054, virilizer



Geprüfte Anwendungen

Produktinformation

68235-1-PBS bindet in WB, IHC, FC (Intra), Indirect ELISA KIAA1429 und zeigt Reaktivität mit human, Maus

Getestete Reaktivität human, Maus
Wirt / Isotyp Maus / IgG1
Klonalität Monoklonal
Typ Antikörper
Immunogen KIAA1429 fusion protein Ag22449
Vollständiger Name KIAA1429
Berechnetes Molekulargewicht 1812 aa, 202 kDa
Beobachtetes Molekulargewicht200-210 kDa
GenBank-ZugangsnummerBC113380
Gene symbol KIAA1429
Gene ID (NCBI) 25962
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein-G-Reinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

VIRMA (KIAA1429) is a key component of m6A methyltransferase (writer) complex that include METTL3, METTL14, WTAP, VIRMA, HAKAI, ZC3H13, and RBM15. VIRMA mediates methylation in the 3'UTR and around the stop codon, thus affecting alternative polyadenylation. VIRMA has been reported to act as an oncogenic factor in breast cancer and liver cancer. KIAA1429 exhibits differential nuclear and cytoplasmic distribution in colorectal cancer samples, and high cytoplasmic expression of KIAA1429 is associated with poor response to chemotherapy. BRAF-mediated phosphorylation of KIAA1429 facilitates its aggregation in the cytoplasm. Furthermore, cytoplasmic KIAA1429 promotes WNT pathway activation by binding and stabilizing FZD7, thereby further enhancing cancer stemness and oxaliplatin resistance (PMID: 40611274).